← All trials
NCT04970719
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jul 21, 2021
- Last posted
- Aug 27, 2021
- Enrollment
- 382
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bangladesh Institute of Research and Rehabilitation in DiabetesLead sponsor
- Bangladesh Institute of Research and Rehabilitation in DiabetesReponsible party - principal investigator
- BIRDEM General HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.